Summary | |
---|---|
Symbol | KRT17 |
Name | keratin 17, type I |
Aliases | PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17 |
Chromosomal Location | 17q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm |
Domain |
PF00038 Intermediate filament protein |
Function |
Type I keratin involved in the formation and maintenance of various skin appendages, specifically in determining shape and orientation of hair (By similarity). Required for the correct growth of hair follicles, in particular for the persistence of the anagen (growth) state (By similarity). Modulates the function of TNF-alpha in the specific context of hair cycling. Regulates protein synthesis and epithelial cell growth through binding to the adapter protein SFN and by stimulating Akt/mTOR pathway (By similarity). Involved in tissue repair. May be a marker of basal cell differentiation in complex epithelia and therefore indicative of a certain type of epithelial "stem cells". Acts as a promoter of epithelial proliferation by acting a regulator of immune response in skin: promotes Th1/Th17-dominated immune environment contributing to the development of basaloid skin tumors (By similarity). May act as an autoantigen in the immunopathogenesis of psoriasis, with certain peptide regions being a major target for autoreactive T-cells and hence causing their proliferation. |
Biological Process |
GO:0001558 regulation of cell growth GO:0001942 hair follicle development GO:0006417 regulation of translation GO:0008544 epidermis development GO:0009913 epidermal cell differentiation GO:0010608 posttranscriptional regulation of gene expression GO:0016049 cell growth GO:0022404 molting cycle process GO:0022405 hair cycle process GO:0030216 keratinocyte differentiation GO:0030307 positive regulation of cell growth GO:0031069 hair follicle morphogenesis GO:0031424 keratinization GO:0034248 regulation of cellular amide metabolic process GO:0034250 positive regulation of cellular amide metabolic process GO:0042303 molting cycle GO:0042633 hair cycle GO:0042634 regulation of hair cycle GO:0042635 positive regulation of hair cycle GO:0043588 skin development GO:0045103 intermediate filament-based process GO:0045104 intermediate filament cytoskeleton organization GO:0045109 intermediate filament organization GO:0045682 regulation of epidermis development GO:0045684 positive regulation of epidermis development GO:0045727 positive regulation of translation GO:0045927 positive regulation of growth GO:0048730 epidermis morphogenesis GO:0051797 regulation of hair follicle development GO:0051798 positive regulation of hair follicle development GO:0098773 skin epidermis development |
Molecular Function |
GO:0005200 structural constituent of cytoskeleton GO:0032395 MHC class II receptor activity GO:0042287 MHC protein binding GO:0042289 MHC class II protein binding |
Cellular Component |
GO:0005882 intermediate filament GO:0045111 intermediate filament cytoskeleton |
KEGG | - |
Reactome |
R-HSA-1266738: Developmental Biology R-HSA-6805567: Keratinization |
Summary | |
---|---|
Symbol | KRT17 |
Name | keratin 17, type I |
Aliases | PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17 |
Chromosomal Location | 17q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between KRT17 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between KRT17 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | KRT17 |
Name | keratin 17, type I |
Aliases | PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17 |
Chromosomal Location | 17q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of KRT17 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | KRT17 |
Name | keratin 17, type I |
Aliases | PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17 |
Chromosomal Location | 17q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of KRT17 in various data sets.
|
Points in the above scatter plot represent the mutation difference of KRT17 in various data sets.
|
Summary | |
---|---|
Symbol | KRT17 |
Name | keratin 17, type I |
Aliases | PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17 |
Chromosomal Location | 17q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KRT17. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | KRT17 |
Name | keratin 17, type I |
Aliases | PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17 |
Chromosomal Location | 17q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KRT17. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KRT17. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | KRT17 |
Name | keratin 17, type I |
Aliases | PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17 |
Chromosomal Location | 17q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KRT17. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | KRT17 |
Name | keratin 17, type I |
Aliases | PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17 |
Chromosomal Location | 17q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of KRT17 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | KRT17 |
Name | keratin 17, type I |
Aliases | PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17 |
Chromosomal Location | 17q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between KRT17 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | KRT17 |
Name | keratin 17, type I |
Aliases | PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17 |
Chromosomal Location | 17q21.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting KRT17 collected from DrugBank database. |
There is no record. |